Abstract: Organ transplantation is the most effective treatment for end-stage organ failure, however, post-operative acute and chronic rejection is one of the major reasons for the loss of graft function.Therefore, safe and reasonable use of immunosuppressants is of vital importance.However, the dosage of immunosuppressants is difficult to determine due to their narrow therapeutic window and considerable inter-individual variations in pharmacokinetics and pharmacodynamics.This paper reviewed the latest research progress in genetic polymorphisms related to pharmacokinetics and pharmacodynamics of commonly used immunosuppressants after organ transplantation, including tacrolimus, cyclosporine, mycophenolic acid, sirolimus, everolimus, glucocorticoids and antibodies, aiming to provide reference for the pharmacogenomics-guided personalized immunosuppression therapy after organ transplantation.